Advances in Chemistry

Advances in Chemistry / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 131974 | https://doi.org/10.1155/2014/131974

Namdeo R. Jadhav, Ramesh S. Kambar, Sameer J. Nadaf, "Dual Wavelength Spectrophotometric Method for Simultaneous Estimation of Atorvastatin Calcium and Felodipine from Tablet Dosage Form", Advances in Chemistry, vol. 2014, Article ID 131974, 6 pages, 2014. https://doi.org/10.1155/2014/131974

Dual Wavelength Spectrophotometric Method for Simultaneous Estimation of Atorvastatin Calcium and Felodipine from Tablet Dosage Form

Academic Editor: Yun Wei
Received24 May 2014
Revised17 Jul 2014
Accepted29 Jul 2014
Published21 Aug 2014

Abstract

Atorvastatin calcium (ATR) and felodipine (FEL) are beneficial in combination for elderly people in management of hypertension and atherosclerosis. Aim of present study is to develop simple, accurate, and precise method for simultaneous quantitative estimation of ATR and FEL from combined tablet dosage form. Method involves simultaneous equation, using acetonitrile—double distilled water (70 : 30)—common solvent showing absorption maxima at 245 and 268 nm. Calibration curves determination for both drugs has been carried out in 0.1 N HCl, phosphate buffer pH 6.8, and acetonitrile (ACN)—water (70 : 30 V/V). Linearity range was observed in the concentration range of 2 to 12 µg/mL for FEL and 20 to 100 µg/mL for ATR. Percent concentration estimated for ATR and FEL was 100.12 ± 1.03 and 99.98 ± 0.98, respectively. The method was found to be simple, economical, accurate and precise and can be used for quantitative estimation of ATR and FEL.

1. Introduction

Atorvastatin (ATR) is chemically described as [R-(, )]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid (Figure 1). It is a member of the drug class known as statins, used for lowering blood cholesterol [1]. It also stabilizes plaque and prevents strokes through anti-inflammation and other mechanisms. It inhibits HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Inhibition of this enzyme stops the reduction of HMG-CoA to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases cholesterol synthesis and ultimately increases expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes [2, 3].

Felodipine (FEL) is a 1, 4 dihydropyridine derivative, that is, chemically described as ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(2,3 dichlorophenyl)-3,5-pyridinedicarboxylate. It is a dihydropyridine calcium channel blocker used mainly for the management of hypertension and angina pectoris like the other calcium channel blockers [4].

Literature survey reveals that spectrophotometric and chromatographic methods, and a stability-indicating LC method, have been reported for determination of ATR in pharmaceutical preparations in combination with other drugs [513]. Several chromatographic and spectrophotometric methods have been reported for felodipine assay [1418]. However, most of the analytical methods developed for the quantization of ATR and FEL involve analysis of single component or combination with other drugs. No effective method has been reported for quantitative estimation of ATR and FEL from combined dosage form.

2. Material and Methods

Atorvastatin calcium and felodipine were kindly gifted by Cipla Ltd., Goa, India. Acetonitrile (Loba Chemie Pvt. Ltd., Mumbai, India) and other chemicals used are of analytical grade. Distilled water was prepared in laboratory.

2.1. Preparation of Bilayered Tablet

Bilayered tablets of total weight of 300 mg each, containing 150 mg immediate release layer of ATR (10 mg API) and 150 mg of sustained release layer of FEL (10 mg API), were prepared by initially adding FEL granules to die of RIMEK minipress (Karnavati engineering, Gujarat, India) and compressed, above which ATR blend was poured and allowed to undergo for the final compression to prepare the bilayered tablet using 8 mm flat faced punches.

2.2. Standard Stock Solution
2.2.1. In 0.1 N HCl

Standard stock solution was prepared by dissolving 10 mg of ATR and 10 mg of FEL separately in 100 mL of volumetric flask containing 10 mL of 0.1 N HCl. Then, the final volume of the solution was made up to 100 mL with 0.1 N HCl to get stock solution of 100 µg/mL. Adequate quantities were sampled out from the standard stock solution in 10 mL volumetric flask to get concentration of 10, 20, 30, 40, 50, and 60 µg/mL ATR and 2, 4, 6, 8, 10, and 12 µg/mL FEL. Then, the absorbances of the solution was measured at 268 nm ( max of FEL) and 245 nm ( max of ATR) using double beam UV visible spectrophotometer against 0.1 N HCl as blank.

2.2.2. In Phosphate Buffer pH 6.8

All the above procedure was repeated using phosphate buffer pH 6.8 instead of 0.1 N HCl. Calibration curve of ATR and FEL in 0.1 N HCl and phosphate buffer (PB) pH 6.8 are shown in Figures 2 and 3, respectively. Absorbance values are shown in Table 1.


FELATR
Concentration (μg/mL)AbsorbanceConcentration (μg/mL)Absorbance
268 nm245 nm268 nm245 nm

200.170690.0508520.128780.02782
400.339710.1007240.247560.05264
600.520230.1525660.370960.08296
800.682750.2140180.505120.11161
1000.848330.25425100.623680.13909
120.767920.16704

2.3. UV Method Development and Optimization
2.3.1. Selection of Common Solvent

ACN—double distilled water (70 : 30% V/V)—was selected as common solvent for developing spectral characteristics of drugs. The selection was made after assessing the solubility of both drugs in different solvents.

2.3.2. Preparation of Standard Drug Solution

(1) ATR Standard Stock Solution (100 μg/mL). Accurately weighed quantity of Atorvastatin calcium (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.

(2) FEL Standard Stock Solution (100 μg/mL). Accurately weighed quantity of felodipine (10 mg) was transferred into 100 mL volumetric flask dissolved in 60 mL of ACN—water (70 : 30% V/V)—and diluted up to mark with same solvent. This will give a stock solution having strength of 100 μg/mL.

2.3.3. Construction of Calibration Curve

(1) Calibration Curve for ATR. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 20 to 100 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.

(2) Calibration Curve for FEL. Different aliquots were withdrawn from the standard stock solution and diluted with appropriate quantity of ACN—water (70 : 30% V/V)—to get a series of concentration ranging from 2 to 12 μg/mL. Absorbance was measured at different concentrations and the calibration curve was prepared by plotting absorbance versus concentration.

2.3.4. Selection of Wavelength

By appropriate dilutions of two standard drug solutions with ACN—double distilled water (70 : 30% V/V)—solutions containing 10 μg/mL of ATR and 10 μg/mL of FEL were scanned separately in the range of 200–400 nm to determine the wavelength of maximum absorption for both drugs (Figure 4).

2.3.5. Selection of Method and Wavelength

For quantitative estimation of ATR and FEL, simultaneous equation method employing 245 nm and 268 nm as analytical wavelength was used. The two wavelengths were chosen from the overlain spectra of ATR and FEL. Overlain spectra of ATR and FEL are shown in Figure 5.

2.4. Procedure for Calculating Absorptivity of Both the Drugs at Selected Wavelengths

From standard drug solutions, six works in standard solutions with concentration of 20, 40, 60, 80, and 100 μg/mL for ATR and 2, 4, 6, 8, 10, and 12 μg/mL for FEL were prepared and scanned separately on the selected wavelengths for both the drugs. The absorptivity at selected wavelength was calculated.

2.5. Analysis of Tablet Formulation

Twenty tablets were powdered. Tablet formulation containing ATR 10 mg and FEL 10 mg was analyzed using this method. From the triturates of 3 tablets, an amount equivalent to 10 mg of ATR and 10 mg of FEL was weighed and dissolved in 10 mL of ACN—water (70 : 30% V/V)—and sonicated for 10 min. Then, the solution was filtered through Whatman filter paper number 41 and then final volume of the solution was made up to 100 mL with ACN—double distilled water (70 : 30% V/V)—to get a stock solution containing 100 μg/mL of ATR and 100 μg/mL FEL.

Appropriate aliquots of ATR and FEL within Beer’s law limit were taken and analyzed by the proposed method using the procedure described earlier. The concentration of ATR and FEL present in the sample solution was calculated by using the simultaneous equation, where is the concentration of ATR in gm/lit, is the concentration of FEL in gm/lit, is the absorbance of sample solution at 268 nm, is the absorbance of sample solution at 245 nm, is the absorptivity of FEL at 268 nm, is the absorptivity of ATR at 268 nm, is the absorptivity of FEL at 245 nm, and is the absorptivity of ATR at 245 nm.

2.6. Method Validation
2.6.1. Linearity

In quantitative analysis, the calibration curve was constructed for both ATR and FEL after analysis of consecutively increased concentrations.

2.6.2. Recovery Studies

Accuracy of analysis was determined by performing recovery studies by spiking different concentrations of pure drug in the preanalyzed tablet samples within the analytical concentration range of the proposed method at three different sets at levels of 80, 100, and 120%. The added quantities of the individual drugs were estimated by above method. Intraday precision and interday precision have also been carried out.

2.6.3. Interday Precision

Analysis of drug was performed on two different days and the deviation in the results was observed. Results are shown in Table 4.

2.6.4. Intraday Precision

Analysis of drug was performed on the same day in morning and evening, and the deviation in the results was observed. Results are shown in Table 5.

2.6.5. Ruggedness

Ruggedness of the method was confirmed by the analysis of formulation that was done by the different analysts, using similar operational and environmental conditions.

3. Result and Discussion

Calibration curve of ATR and FEL was plotted by measuring the absorbance of prepared dilutions of the aforesaid different concentrations at their respective wavelength of maximum absorbance (Figures 6 and 7).

3.1. Linearity

Linear regression data showed a good linear relationship over a concentration range of 2 to 12 µg/mL for FEL and 20 to 100 µg/mL for ATR, whereas, Rajesh et al. demonstrated that linearity was within the range of 2–10 μg/mL for each atorvastatin calcium and felodipine [19]. Six point regression data at both wavelengths (268 nm 245 nm) were generated for FEL (Table 2).


Concentration (μg/mL)Absorptivity of FELConcentration (μg/mL)Absorptivity of ATR
268 nm245 nm268 nm245 nm

20.006030.001399200.085330.0254
40.006180.00148400.085390.0266
60.006380.001462600.085480.0282
80.006540.001495800.085620.0299
100.006730.0015161000.085860.0331
120.006980.001543
Mean0.007590.001465Mean0.085530.0286
S.D.0.441.03S.D.1.390.95

3.2. Tablet Analysis

See Table 3.


Label claim (mg/tab)% concentration estimated*

ATR100.12 ± 1.03
FEL99.98 ± 0.98

*Indicates ± SD ().

DayLabel claim (mg/tablet)Amount added (%)Total amount added (mg)Concentration recovered* (mean ± SD) % recovery estimated* (mean ± %SD)

Day 1ATR 108088.02 ± 0.34100.22 ± 1.12
1001010.90 ± 0.7898.10 ± 0.98
1201212.23 ± 0.89103.91 ± 1.23
FEL 108088.17 ± 1.45101.70 ± 1.18
1001010.71 ± 1.78101.68 ± 1.24
1201212.99 ± 1.2599.93 ± 0.98

Day 2ATR 108088.04 ± 1.11101.11 ± 1.25
1001010.08 ± 1.45101.60 ± 1.17
1201212.03 ± 0.34100.64 ± 1.11
FEL 108088.17 ± 1.71101.70 ± 0.65
1001010.22 ± 1.1297.76 ± 0.34
1201212.54 ± 0.34103.60 ± 0.32

*Indicates ± SD ().

Day 1Label claim (mg/tablet)Amount added (%)Total amount added (mg)Concentration recovered* (mean ± SD)% recovery estimated* (mean ± %SD)

MorningATR 108088.04 ± 0.30100.22 ± 1.12
1001010.10 ± 0.3497.10 ± 0.57
1201212.13 ± 0.44102.79 ± 1.52
FEL 108088.27 ± 1.47101.80 ± 1.74
1001010.56 ± 1.78101.32 ± 1.04
1201212.90 ± 1.2899.99 ± 0.91

EveningATR 108088.08 ± 1.18101.64 ± 1.17
1001010.04 ± 1.55101.40 ± 1.87
1201212.05 ± 0.28101.55 ± 1.13
FEL 108088.11 ± 1.54101.28 ± 0.45
1001010.14 ± 1.1799.68 ± 0.56
1201212.99 ± 1.9899.46 ± 0.98

*Indicates ± SD ().
3.3. Recovery Study

The added quantities of added drug were estimated by simultaneous equation (Table 4).

3.4. Interday Precision

Interday precision study was performed and method was found to be precise.

3.5. Intraday Precision

Intraday precision study was performed and method was found to be precise. Recoveries obtained for the two drugs do not differ significantly from 100%, which showed that there was no interference from common excipients used in the formulation indicating accuracy and reliability of the method (Table 5).

3.6. Ruggedness

Ruggedness of the method was tested using different chemical sources of acetonitrile and effects on results were observed and shown in Table 6. From the result, it was found that method has ruggedness.


Label claim
(mg/tablet)
% recovery estimated* (mean ± %SD)
ATRFEL

Source I100/10102.74 ± 0.35101.18 ± 0.31
Source II100/10103.12 ± 0.35103.18 ± 0.62

*Indicates ± SD ().

4. Conclusion

In present study, from the observation of the validation parameters, it can be concluded that the developed method is simple, accurate, reliable, and economical for the simultaneous quantitative estimation of atorvastatin calcium and felodipine from combined dosage form using UV spectrophotometric method.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. B. W. McCrindle, L. Ose, and A. D. Marais, “Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial,” Journal of Pediatrics, vol. 143, no. 1, pp. 74–80, 2003. View at: Publisher Site | Google Scholar
  2. J. Villa and R. E. Pratley, “Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study,” Current Diabetes Reports, vol. 10, no. 3, pp. 173–175, 2010. View at: Publisher Site | Google Scholar
  3. T. McCormack, P. Harvey, R. Gaunt, V. Allgar, R. Chipperfield, and P. Robinson, “Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets,” International Journal of Clinical Practice, vol. 64, no. 8, pp. 1052–1061, 2010. View at: Publisher Site | Google Scholar
  4. M. B. El-Hawary, M. T. khayall, and Z. Isaak, Hand Book of Pharmacology, The Scientific Book Center, S.O.P. Press, Cairo, Egypt, 1978.
  5. S. L. Thamake, S. D. Jadhav, and S. A. Pishawikar, “Development and validation of method for simultaneous estimation of atorvastatin calcium and ramipril from capsule dosage form by first order derivative spectroscopy,” Asian Journal of Research in Chemistry, vol. 2, no. 1, pp. 52–53, 2009. View at: Google Scholar
  6. R. Lakshmana, K. R. Rajeswari, and G. G. Sankar, “Spectrophotometric method for simultaneous estimation of atorvastatin and amlodipine in tablet dosage form,” Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 2, pp. 66–69, 2010. View at: Google Scholar
  7. M. Saravanamuthukumar, M. Palanivelu, K. Anandarajagopal, and D. Sridharan, “Simultaneous estimation and validation of atorvastatin calcium and ubidecarenone (Coenzyme Q10) in combined tablet dosage form by RP-HPLC method,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 2, pp. 36–38, 2010. View at: Google Scholar
  8. L. Joseph, M. George, and B. V. R. Rao, “Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy,” Pakistan Journal of Pharmaceutical Sciences, vol. 21, no. 3, pp. 282–284, 2008. View at: Google Scholar
  9. L. Nováková, D. Šatínský, and P. Solich, “HPLC methods for the determination of simvastatin and atorvastatin,” Trends in Analytical Chemistry, vol. 27, no. 4, pp. 352–367, 2008. View at: Publisher Site | Google Scholar
  10. B. G. Chaudhari, N. M. Patel, and P. B. Shah, “Stability indicating RP-HPLC method for simultaneous determination of atorvastatin and amlodipine from their combination drug products,” Chemical and Pharmaceutical Bulletin, vol. 55, no. 2, pp. 241–246, 2007. View at: Publisher Site | Google Scholar
  11. A. Mohammadi, N. Rezanour, M. Ansari Dogaheh, F. Ghorbani Bidkorbeh, M. Hashem, and R. B. Walker, “A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 846, no. 1-2, pp. 215–221, 2007. View at: Publisher Site | Google Scholar
  12. G. F. Patel, N. R. Vekariya, and R. B. Dholakiya, “Estimation of aspirin and atorvastatin calcium in combine dosage form using derivative spectrophotometric method,” International Journal of Pharmaceutical Research, vol. 2, no. 1, pp. 62–66, 2010. View at: Google Scholar
  13. N. R. Jadhav, R. S. Kambar, and S. J. Nadaf, “RP-HPLC method for simultaneous estimation of atorvastatin calcium and felodipine from tablet dosage form,” Current Pharma Research, vol. 2, no. 4, pp. 637–642, 2012. View at: Google Scholar
  14. A. J. López, V. Martínez, R. M. Alonso, and R. M. Jiménez, “High-performance liquid chromatography with amperometric detection applied to the screening of 1,4-dihydropyridines in human plasma,” Journal of Chromatography, vol. 870, no. 1-2, pp. 105–114, 2010. View at: Google Scholar
  15. A. B. Baranda, R. M. Jiménez, and R. M. Alonso, “Simultaneous determination of five 1,4-dihydropyridines in pharmaceutical formulations by high-performance liquid chromatography-amperometric detection,” Journal of Chromatography A, vol. 1031, no. 1-2, pp. 275–280, 2004. View at: Publisher Site | Google Scholar
  16. J. Gottfries, J. Ahlbom, V. Harang et al., “Validation of an extended release tablet dissolution testing system using design and multivariate analysis,” International Journal of Pharmaceutics, vol. 106, no. 2, pp. 141–148, 1994. View at: Publisher Site | Google Scholar
  17. B. Marciniec, E. Jaroszkiewicz, and M. Ogrodowczyk, “The effect of ionizing radiation on some derivatives of 1,4-dihydropyridine in the solid state,” International Journal of Pharmaceutics, vol. 233, no. 1-2, pp. 207–215, 2002. View at: Publisher Site | Google Scholar
  18. K. Basavaiah, U. Chandrashekar, and H. C. Prameela, “Sensitive spectrophotometric determination of amlodipine and felodipine using iron(III) and ferricyanide,” Farmaco II, vol. 58, no. 2, pp. 141–148, 2003. View at: Publisher Site | Google Scholar
  19. K. Rajesh, R. Rajalakshmi, S. Vijayaraj, and T. Sreelakshmi, “Simultaneous estimation of atorvastatin calcium and felodipine by UV-spectrophotometric method in formulation,” Asian Journal of Research in Chemistry, vol. 4, no. 8, pp. 1202–1205, 2011. View at: Google Scholar

Copyright © 2014 Namdeo R. Jadhav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

4257 Views | 603 Downloads | 1 Citation
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.